Travere Therapeutics (TVTX) Capital Expenditures (2013 - 2025)
Travere Therapeutics (TVTX) posted Capital Expenditures of $140000.0 for Q3 2025, up 70.73% on a QoQ basis from $82000.0 in Q2 2024.
Travere Therapeutics (TVTX) Capital Expenditures (2013 - 2025) Analysis & Trends
Travere Therapeutics' Capital Expenditures history runs 13 years deep, the most recent figure standing at $140000.0 for Q3 2025.
- Quarterly Capital Expenditures changed N/A year-over-year to $140000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $222000.0 (up 107.48% YoY) and the FY2023 annual result came in at $668000.0, up 249.74% from the prior year.
- Capital Expenditures was $140000.0 for Q3 2025 at Travere Therapeutics, up from $82000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.5 million in Q1 2021 and bottomed at $3000.0 in Q2 2023.
- A 5-year average of $441571.4 and a median of $92500.0 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures tumbled 97.09% — and 2024, when it soared 2633.33%.
- Travere Therapeutics' Capital Expenditures stood at $154000.0 in 2021, then tumbled by 80.52% to $30000.0 in 2022, then decreased by 16.67% to $25000.0 in 2023, then jumped by 228.0% to $82000.0 in 2024, then surged by 70.73% to $140000.0 in 2025.
- Business Quant data shows TVTX's Capital Expenditures at $140000.0 in Q3 2025, $82000.0 in Q2 2024, and $25000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 140,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Sep 30, 2022 | 13,000.00 |
| Sep 30, 2022 | 13,000.00 |
| Jun 30, 2022 | 17,000.00 |
| Jun 30, 2022 | 17,000.00 |
| Mar 31, 2022 | 131,000.00 |
| Mar 31, 2022 | 131,000.00 |